Industry: Manufacturing (SIC 2834 — Pharmaceutical Preparations)
Of the 1,000 filings in this window, 20 (2.0%) are routine debt or shelf offerings (form 424B*, FWP, S-3*), which are excluded from the routine rate below because large issuers generate them continuously.
| Form type | Filings in window |
|---|---|
| 4 | 690 |
| 144 | 69 |
| 8-K | 44 |
| SC TO-T/A | 23 |
| SC 13G/A | 22 |
| PX14A6G | 17 |
| 3 | 15 |
| 10-Q | 14 |
| 424B2 | 12 |
| SCHEDULE 13G/A | 11 |
| SC TO-T | 7 |
| SC TO-C | 7 |
| FWP | 6 |
| CORRESP | 6 |
| Metric | Value |
|---|---|
| Window covered | 2021-12-16 → 2026-10-08 |
| Span | 4.81 years |
| All filings in window | 1,000 |
| Routine filings (offerings excluded) | 980 |
| Routine filings per year | 204 |
| Insider forms as share of routine filings | 70.8% |
| Routine debt/shelf offering share | 2.0% |
Former names on record: LILLY ELI & CO, LILLY ELI & CO ET AL
| Field | Value |
|---|---|
| CIK | 0000059478 |
| Tickers | LLY |
| Exchange | NYSE |
| State of incorporation | IN |
| Fiscal year end | 1231 |
| Filer category | Large accelerated filer |
Raw EDGAR source for this entity: submissions/CIK0000059478.json · EDGAR filings list